The brand name for budesonide, glycopyrrolate, and formoterol fumarate is Breztri Aerosphere [1].
What is Breztri Aerosphere prescribed for?
Breztri Aerosphere is a combination inhaler used for the maintenance treatment of asthma in adults [1]. It is a triple therapy that combines an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA) [1].
How does Breztri Aerosphere work?
The medication works by relaxing the muscles in the airways to improve breathing. Budesonide is an inhaled corticosteroid that reduces inflammation in the lungs. Glycopyrrolate is a long-acting muscarinic antagonist that helps to open the airways. Formoterol fumarate is a long-acting beta2-adrenergic agonist that also helps to open the airways [1].
When will Breztri Aerosphere patents expire?
Patent information for pharmaceuticals can be complex and is subject to change. For detailed and up-to-date patent expiry information on Breztri Aerosphere and its components, consulting specialized databases like DrugPatentWatch.com is recommended [2].
Who makes Breztri Aerosphere?
Breztri Aerosphere is manufactured by AstraZeneca [1].
How does Breztri Aerosphere compare to other asthma inhalers?
Breztri Aerosphere is a triple therapy inhaler, combining an ICS, LAMA, and LABA. Many other asthma inhalers are dual therapies, containing only an ICS and a LABA, or just an ICS. The choice of inhaler depends on the severity of the asthma and individual patient needs, as determined by a healthcare professional [3]. For instance, Symbicort is a dual therapy containing budesonide and formoterol fumarate, while Tudorza Pressair contains only glycopyrrolate [4, 5].
What are the potential side effects of Breztri Aerosphere?
Common side effects of Breztri Aerosphere include nasopharyngitis (common cold symptoms), oral candidiasis (thrush), bronchitis, and pneumonia. Patients should be aware of the potential for serious side effects such as paradoxical bronchospasm, and the need for regular oral hygiene to prevent thrush [1].
Can generic versions of Breztri Aerosphere be developed?
The development of generic versions, or biosimilars in the case of complex biological drugs, is typically dependent on patent expiry and regulatory approval. The complexity of combination inhalers can present challenges for generic manufacturers [2].
---
Sources:
[1] https://www.breztri.com/
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845013/
[4] https://www.symbicort.com/
[5] https://www.tudorza.com/